Navigation Links
The Trendlines Group Announces Co-development Agreement with Endo
Date:11/13/2012

TEL AVIV, Israel, November 13, 2012 /PRNewswire/ --

The Trendlines Group today announced it has entered into an R&D agreement aimed at co-developing novel medical devices and technologies within the areas of pain and urology, a strategic focus  of U.S.-based Endo Health Solutions Inc. (Nasdaq: ENDP).  

The work will be conducted by Trendlines Labs, the technology development arm of The Trendlines Group.  Trendlines Labs is co-located with the Misgav Venture Accelerator - The Trendlines Group's incubator focused exclusively on the development of medtech innovations.  Misgav was named "Best Incubator" by Israel's Office of the Chief Scientist of the Ministry of Industry, Trade and Labor in 2010. Trendlines portfolio company Stimatix (http://www.stimatix-gi.com) was named Israel's best start-up in 2012.

D. Todd Dollinger, Chairman and CEO of Trendlines, stated, "Our work with Endo furthers our market reach and is instrumental to our achieving our mission of creating and developing businesses to improve the human condition."  

Dr. Sujat Sukthankar, Vice President, Device R&D, at Endo said, "The Trendlines-Endo agreement is in line with our stated vision of sourcing innovation globally.  This partnership complements and bolsters our own internal innovation and product development efforts in the areas of pain and urology.  Through this partnership, we are excited to participate in the vibrant medical technology community in Israel. "  

Endo Health Solutions Inc. (http://www.endo.com) is a U.S.-based diversified healthcare company that is redefining healthcare value by finding solutions for the unmet needs of patients along care pathways for pain management, pelvic health, urology, endocrinology and oncology. Through its operating companies: Endo Pharmaceuticals, Qualitest, AMS and HealthTronics, Endo is dedicated to improving care through a combination of branded products, generics, devices, technology and services that creates maximum value for patients, providers and payers alike.

About The Trendlines Group

The Trendlines Group (http://www.trendlines.com) creates and develops businesses to improve the human condition.  Principally through its two Israeli government-licensed business accelerators, Trendlines invests in innovation-based businesses in the areas of medtech and agritech, nurturing high-promise companies while mitigating seed-stage investment risk. The Trendlines group owns the Misgav Venture Accelerator (http://www.misgav-venture.com) which invests in and incubates promising medical device companies and Trendlines Labs, which acts as Trendlines' in-house invention factory, inventing solutions to unmet market needs.

Media relations:
Efrat Sherer-Kaduri
Ofir Shpigel Media and Public Relations
+972-4-9535030


'/>"/>
SOURCE The Trendlines Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. China Cord Blood Corporation Announces Completion of Strategic Partnership with Cordlife Group Limited
2. Apexigen Announces Initiation of Clinical Trials By Its Partner, Simcere Pharmaceutical Group
3. MiMedx Group Announces Record Third Quarter Results And Raises Revenue Estimates For The Year
4. MiMedx Group to Present at the Craig-Hallum 2012 Alpha Select Conference
5. MiMedx Group to Present at the BIOX; Noble Financial Capital Markets Life Sciences Exposition
6. VWR International, LLC Acquires Sovereign Group
7. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year
8. China Cord Blood Corporation and Cordlife Group Limited Foster Closer Alliance Across Asia
9. Astrix Technology Group Awarded Department of Homeland Security BioWatch Laboratory Staffing Contract
10. EAS Consulting Group Realigns Its Management for Growth
11. MiMedx Group Raises over $4.9 Million through the Exercise of Callable Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... Microbial genomics leader ... grant award has been made to Dr. Renato Polimanti of Yale University School ... the oral microbiome. Grant proposals have been vetted by the company’s scientific review ...
(Date:12/2/2016)...  The Multiple Myeloma Research Foundation (MMRF) today announced ... SM —the largest and most comprehensive study driving new ... be presented at the 58 th American Society ... San Diego from December 3-6. The ... well as identify pathways and targets for new drug ...
(Date:12/2/2016)... San Antonio Texas (PRWEB) , ... ... ... announced today that it will share findings demonstrating the value of DNA ... cancer patients at this year’s San Antonio Breast Cancer Symposium. Using molecular ...
(Date:12/2/2016)... , ... December 01, 2016 , ... ... long-term client Nanowear on their recent FDA Class II 510(k) clearance for their ... significant hurdle in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. ...
Breaking Biology Technology:
(Date:11/22/2016)... November 22, 2016 According to the new market ... Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact ... MarketsandMarkets, the market is expected to grow from USD 10.74 Billion in ... 16.79% between 2016 and 2022. Continue Reading ... ...
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology ... object recognition technologies, today announced that the MegaMatcher ... cards was submitted for the NIST Minutiae ... passed all the mandatory steps of the evaluation ... is a continuing test of fingerprint templates used ...
(Date:11/17/2016)... -- Global Market Watch: Primarily supported by ownership ... and Academics) market is to witness a value of US$37.1 ... highest Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen ... period 2014-2020. North America is not ... Europe at 9.56% respectively. Report Focus: ...
Breaking Biology News(10 mins):